Cresemba (isavuconazonium sulfate) / Astellas, Basilea, Pfizer, Grupo Biotoscana, Hikma, Laboratoire Riva, Asahi Kasei, Knight Therap, MedCap AB - LARVOL DELTA

Post-tuberculosis lung disease and pulmonary aspergillosis management: challenges and considerations. (PubMed, Expert Rev Anti Infect Ther) - "Randomized trials demonstrate the superiority of 12-month itraconazole, comparative efficacy of itraconazole and voriconazole, and the emerging role of posaconazole, isavuconazole, and nebulized amphotericin B are summarized. CPA remains severely underdiagnosed due to overlapping features with TB, limited diagnostic access, and absence from national TB programs. Integrating CPA diagnostic bundles into national TB programs, standardizing serologic thresholds, ensuring antifungal stewardship, and developing validated composite response criteria are essential to improving outcomes in PTLA populations."

Journal • Bronchiectasis • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

STEROID IN A CASE OF COCCIDIOIDOMYCOSIS MENINGOENCEPHALITIS WITH COMPLICATED HYDROCEPHALUS, WHEN THE LEFT AND RIGHT STOPPED TALKING. (WRMC 2026) - "Case Report: A 24-year-old Hispanic male with 4 years of fentanyl abuse and severe malnutrition presented to our institution after 5 months of weight loss, cough, headache, recent onset of ataxia, and 3 days of daily seizures...Due to the inoperable epidural abscess, Liposomal amphotericin B (LamB) was added...MRI brain showed worsening of basilar leptomeningeal enhancement (Figure1), so fluconazole was changed to isavuconazole...He was placed on 20 mg of dexamethasone and responded clinically. Left EVD was clamped and eventually removed, and bilateral shunting was avoided. The patient was de-escalated from the neurology intensive care Figure 1: MRI brain shows extensive basilar enhancement"

Clinical • Ataxia • CNS Disorders • Cough • Epilepsy • Movement Disorders • Respiratory Diseases • Ventriculomegaly

COCCIDIOIDOMYCOSIS PULMONARY NODULE, A MASTER OF DISGUIS (WRMC 2026) - "Posaconazole 400 mg was started to cover aspergillosis and other molds. His pleural fluid grew coccidioides immitis, confirmed by MALDI-TOF (ARUP), and his treatment was switched to fluconazole 800 mg daily...His treatment was changed to isavuconazole...African American and Filipino patients are particularly at risk for complications and dissemination. Making a prompt diagnosis and initiation of treatment is paramount."

Cardiovascular • Chronic Kidney Disease • Diabetes • Endocrine Disorders • Hypertension • Infectious Disease • Metabolic Disorders • Nephrology • Renal Disease • Respiratory Diseases • Type 2 Diabetes Mellitus

SEVERE DISSEMINATED COCCIDIOIDOMYCOSIS WITH VERTEBRAL INVOLVEMENT PRESENTING WITH SUPERIMPOSED BACTEREMIA AND LONGSTANDING ICHTHYOSIS LIKE SKIN DISEASE (WRMC 2026) - "Cavity fluid grew pseudomonas aeruginosa and repeat blood cultures grew Capnocytophaga Sputigena. He is being treated with isavuconazonium, vancomycin, meropenem, and IV Amphotericin B liposomal and Niacin and thiamine supplementation."

Atopic Dermatitis • Cachexia • CNS Disorders • Dermatology • Hematological Disorders • Hepatitis C • Human Immunodeficiency Virus • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Septic Shock • Vitiligo

Which trial do we need? Defining the optimal duration of antifungal therapy for invasive pulmonary aspergillosis: duration of therapy in invasive aspergillosis. (PubMed, Clin Microbiol Infect) - No abstract available

Journal • Hematological Disorders • Pulmonary Disease • Respiratory Diseases

Comment on: "Therapeutic Drug Monitoring of Isavuconazole: Trends and Update". (PubMed, Int J Antimicrob Agents) - No abstract available

Journal

Adjunctive hyperbaric oxygen combined with surgery and antifungal therapy for the management of soft tissue mucormycosis: a case report and review of the literature. (PubMed, J Mycol Med) - "We report a case of Mucor circinelloides ankle infection in an immunocompetent man following a high-energy motorcycle accident, which has successfully been treated by surgery (multiple debridements, arthrodesis, soft tissue defect reconstruction with flap and skin graft), systemic antifungal therapy (initial liposomal amphotericin B followed by isavuconazole) and hyperbaric oxygen. This case highlights the therapeutic challenges and need for a multidisciplinary approach of such infection."

Journal • Immunology • Infectious Disease • Inflammation • Rheumatology

PERSISTING FEVER AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A CASE REPORT OF A RARE INFECTION WITH LOMENTOSPORA PROLIFICANS (EBMT 2026) - "Cytoreductive therapy with hydroxyurea was initiated immediately after diagnosis, with no other prior antineoplastic treatment administered. Conditioning with fludarabine, thiotepa, and melphalan was started 7 months after the initial diagnosis...The patient received an HLA-identical unrelated male donor peripheral blood stem cell graft, with graft-versus-host disease prophylaxis comprising cyclosporine, mycophenolate mofetil, and anti-thymocyte globulin (ATG)...On day −3, the patient developed febrile neutropenia and broad-spectrum antibiotic treatment (piperacillin/tazobactam) was initiated. Recurrent fever on day +1 led to escalation to meropenem and a switch from fluconazole to posaconazole; blood cultures remained negative.Under these measures, the fever persisted...On day +11, increasing somnolence, pathological breathing pattern, and new oxygen requirement prompted sampling of peripheral and central blood cultures and empiric addition of linezolid and..."

Case report • Clinical • Bone Marrow Transplantation • Chronic Myelomonocytic Leukemia • Febrile Neutropenia • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Neutropenia • Respiratory Diseases • Septic Shock • Transplantation • ASXL1 • NRAS • RUNX1 • SETBP1 • SRSF2

MICAFUNGIN AS ANTIFUNGAL PROPHYLAXIS DURING THE PRE-ENGRAFTMENT PERIOD OF ALLO-HSCT. ANALYSIS OF A 450-PATIENT COHORT (EBMT 2026) - " Table 1: "Baseline characteristics of patients undergoing allo-HSCT receiving micafungin prophylaxis"; n = 450HSCT: Hematopoietic stem cell transplantation; AML: Acute myeloid leukemia; ALL: Acute lymphoblastic leukemia; MDS: Myelodysplastic síndrome; GVHD: Graft-versus-host disease; MAC: Myeloablative conditioning; RIC: Reduced-intensity conditioning; Cs: Cyclosporine; MTX: Methotrexate; MF: Mycophenolate mofetil; CF post: Post-transplant cyclophosphamide; ATG: Antithymocyte globulin...Two azole-resistant and one anidulafungin-resistant Candida isolates were detected...Among patients with proven or possible IFI (n=34), 26.5% had received corticosteroids during the pre-engraftment period.Antifungal treatments were heterogeneous: liposomal amphotericin B (37.9%), isavuconazole (24.1%), and double-agent combinations (24.1%), mainly in critically ill patients with severe pneumonia or intensive care needs.IFI was the primary cause of death in 3 of 19 patients..."

Clinical • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Candidiasis • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Mucositis • Myelodysplastic Syndrome • Pneumonia • Respiratory Diseases

REAL-WORLD EXPERIENCE WITH ISAVUCONAZOLE IN ALLOGENEIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS IN SPAIN (EBMT 2026) - "In our experience, ISV appears to be safe and effective for treatment and prophylaxis of IFI in paediatric patients and shows a favorable toxicity profile. A significant proportion of patients showed ISV plasma levels out of the therapeutic range, highlighting the importance of monitoring levels in this population."

Clinical • Real-world • Real-world evidence • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology • Infectious Disease • Pediatrics • Respiratory Diseases • Transplantation

SUBTHERAPEUTIC CYCLOSPORINE CONCENTRATIONS DESPITE STANDARD DOSING IN HSCT PRACTICE (EBMT 2026) - "(p>0.05)Drug–drug interactions were identified in 21 cases receiving concurrent antifungal therapy (6 on voriconazole, 12 on isavuconazole, 3 on fluconazole)...Only 1 case (8.3%) with isavuconazole met target level.Cyclophosphamide was included in the conditioning regimen for 96 patients; the remaining four cases involved second or later transplants, limiting the ability to assess the contribution of cyclophosphamide to cyclosporine clearance... The standard cyclosporine dose of 3 mg/kg/day frequently fails to achieve target therapeutic concentrations in HSCT patients. Despite a wide distribution of BMI in the cohort, no clear association between body size and achieving therapeutic levels was observed when dosing was based on lower body weight. This finding suggests that using lower body weight for dosing is appropriate."

Bone Marrow Transplantation • Graft versus Host Disease • Immunology • Obesity

The Activity of FDA-Approved Prodrug Isavuconazonium Sulfate and Its Major Metabolite Isavuconazole Against Naegleria fowleri. (PubMed, Pharmaceutics) - "Combination with amphotericin B was synergistic without eliciting toxicity on mammalian cells. Our findings, together with the use of intravenous and oral formulations of isavuconazonium to treat pediatric and adult patients, support further in vivo efficacy study of isavuconazonium for its potential use for the treatment of PAM."

FDA event • Journal • CNS Disorders • Infectious Disease • Pediatrics

Primary mediastinal mucormycosis presenting with hoarseness: a case report. (PubMed, J Med Case Rep) - "Mediastinal mucormycosis, though rare, should be considered in patients with atypical presentations including hoarseness, particularly those with chronic illnesses. Early diagnosis through tissue biopsy and timely antifungal treatment is essential for better prognosis."

Journal • Chronic Obstructive Pulmonary Disease • Hematological Malignancies • Immunology • Infectious Disease • Lung Cancer • Lymphoma • Oncology • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases • Solid Tumor • Thymoma • Thymus Cancer

New advances and future prospect in antifungal therapy for invasive pulmonary aspergillosis (PubMed, Zhonghua Jie He He Hu Xi Za Zhi) - "New antifungal agents, such as isavuconazole, new formulations of posaconazole, liposomal amphotericin B, rezafungin, and eravacycline, exhibit distinct pharmacokinetic, pharmacodynamic, and safety profiles. Nanoparticle delivery systems and inhaled formulations have increased drug concentrations at the airway site while reducing systemic adverse effects. Future research will focus on new drug development targeting fungal protein targets, multi-target approaches, and immunomodulatory therapies."

Journal • Review • Pulmonary Disease • Respiratory Diseases

Isavuconazole activity against moulds in ICU and non-ICU infections (ESCMID Global 2026) - No abstract available

Infectious Disease

Pharmacovigilance insights: safety profiles of antifungal agents for invasive aspergillosis. (PubMed, Front Pharmacol) - "The safety profiles of FDA-approved antifungal agents, triazoles (Voriconazole, Posaconazole, Isavuconazole), polyenes (Amphotericin B), and echinocandins (Caspofungin), are not yet fully characterized in real-world settings. Amphotericin B and Caspofungin are associated with severe renal/hepatic toxicities and higher mortality, while Isavuconazole and Posaconazole may offer safer alternatives with delayed AE onset. Clinicians should prioritize drug-specific risks when tailoring treatment for IA patients."

Adverse events • Journal • Cholestasis • Hepatology • Ocular Inflammation • Ophthalmology • Optic Neuritis • Pain • Pulmonary Disease • Renal Disease • Respiratory Diseases

Isavuconazole as initial antifungal therapy combined with surgical management of pediatric pulmonary mucormycosis: a case report and literature review. (PubMed, Front Pediatr) - "All of the aforementioned interventions helped buy time for subsequent surgical treatment, leading to the curing of the child. Isavuconazole may represent an effective and safe therapeutic option as first-line monotherapy for pediatric mucormycosis."

Journal • Diabetes • Infectious Disease • Metabolic Disorders • Pediatrics

Treatment of pulmonary mucormycosis: current concepts. (PubMed, Expert Rev Anti Infect Ther) - "We emphasize aggressive host factor optimization (glycemic control, immunosuppression reduction) and outline the evidence-based antifungal strategy: liposomal amphotericin B (L-AMB) for induction, followed by oral maintenance (posaconazole or isavuconazole)...Combination antifungal therapy lacks definite evidence and should be reserved for severe or refractory cases. Future research priorities include prospective evaluation of treatment strategies, host-directed therapies, emerging antifungals (oral nanocrystal amphotericin, fosmanogepix, etc.), and systematic assessment of adjunctive modalities."

Journal • Review • Immunology • Infectious Disease • Nephrology • Renal Disease • Transplantation

Invasive Infection With Purpureocillium lilacinum: A Case of Fungal Peritonitis. (PubMed, Cureus) - "After initial treatment failure with fluconazole, the patient was successfully treated with a long course of isavuconazole. This case highlights just the fourth reported case of P. lilacinum peritonitis in the medical literature and the first treated with isavuconazole."

Journal • Infectious Disease • Pain

Preserving the Antimycobacterial Drug Arsenal: A Case Report of Disseminated Mycobacterium Avium Disease (IWLH 2026) - "The patient was treated with clarithromycin, ethambutol, rifabutin, moxifloxacin, and cycloserine for two years, with amikacin added for the first six months, inducing ototoxicity...A salvage regimen was initiated, including amikacin, tedizolid, clofazimine, ceftazidime/avibactam, isoniazid, delamanide, and ethambutol, as well as antiepileptic treatment and IFNγ administration...Intravenous dexamethasone was administered with intensified NTM treatment, but blood cell counts continued to decline, and inflammatory markers (CRP, PCT) remained high. Due to previous Gram-negative infections, his regimen was modified to include daptomycin, meropenem/vaborbactam, and colistimethate. Candida glabrata was identified in port cultures, necessitating port removal and initiation of isavuconazole. He was placed on dual beta-lactam therapy (meropenem and ceftriaxone) combined with clofazimine, isoniazid, linezolid, cycloserine, bedaquiline, and pretomanid...Conclusions This case..."

Case report • Clinical • CNS Disorders • Epilepsy • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hemophagocytic lymphohistiocytosis • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Pulmonary Disease • Respiratory Diseases • Septic Shock • IFNG • IL12A

Emerging Applications of Triazole Antifungal Drugs. (PubMed, Int J Mol Sci) - "The clinical utility of key antifungal agents, namely, posaconazole, isavuconazole, and voriconazole, is critically evaluated. We also examine the potential role of emerging agents such as opelconazole, which enables targeted pulmonary delivery and prolonged epithelial retention, representing a promising approach to IFI prevention. Drug-specific considerations, including pharmacokinetics, drug-drug interactions, toxicity profiles, and cost-effectiveness, are analyzed in the context of clinical decision-making. Finally, we emphasize the importance of tailoring antifungal strategies based on leukemia subtype, immunosuppressive status, and individual patient factors to optimize outcomes and support antifungal stewardship in hematologic malignancies."

Journal • Review • Acute Myelogenous Leukemia • Chemotherapy-Induced Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Neutropenia • Oncology

Isavuconazole in the treatment of acute invasive fungal sinusitis: two case reports and literature review. (PubMed, Front Med (Lausanne)) - "Literature comparisons further validate these findings, demonstrating that the efficacy of the new triazole drug isavuconazole in treating invasive aspergillosis and mucormycosis significantly surpasses that of amphotericin B, with efficacy comparable to voriconazole (p < 0.05). These results provide valuable guidance for clinical medication decisions."

Journal • Infectious Disease • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases • Sinusitis

Successful Treatment of Probable Disseminated Mucormycosis Using Liposomal Amphotericin B and Isavuconazole in Myelodysplastic Syndrome: A Case Report and Literature Review. (PubMed, Int J Infect Dis) - "Our case highlights the importance of prompt diagnosis and timely initiation of therapy for mucormycosis and indicates that combination antifungal therapy may be an effective approach to managing severe disseminated mucormycosis in immunocompromised patients."

Journal • Hematological Malignancies • Infectious Disease • Myelodysplastic Syndrome • Oncology

A Pilot Study Evaluating Acalabrutinib for the Treatment of Relapsed/Refractory Primary and Secondary Central Nervous System Lymphomas (ASH 2022) - P2 | "Prophylactic administration of the antifungal agent isavuconazole will be mandatory while subjects receive acalabrutinib. This decision is based on cases of invasive aspergillosis in studies evaluating ibrutinib...Key exclusion criteria include: previous BTKi exposure; anticoagulation with warfarin; strong CYP3A4 inhibitor that cannot be stopped; severe hepatic insufficiency; inability to take oral medication...Additionally, the utility of 82Rubidium as a positron emission tomography-radiotracer will be evaluated (at screening and prior to cycle 3 and cycle 7) in the first five subjects at the University of North Carolina who consent to this scan. Mental status and cognitive function will be evaluated with the mini-mental status examination (MMSE) at screening then every 6 months."

Clinical • Atrial Fibrillation • Cardiovascular • CNS Lymphoma • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Hepatitis C • Liver Failure • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pulmonary Disease • Respiratory Diseases • CXCR4 • MYD88

Impact of body mass index and serum albumin levels on isavuconazole plasma concentrations in patients with haematological malignancies (ESCMID Global 2026) - No abstract available

Clinical • Hematological Malignancies • Oncology